R&G Pharma
30133347.203.35% ( +1.53 )
R&G Pharma (301333)
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and develop...
- Open
- 46.00
- High
- 47.67
- Low
- 45.61
- Prev. Close
- 45.67
- Volume
- 19.91K
- Turnover
- 93.87M
- Avg Price
- 47.15
- Bid/Ask Ratio
- --
- Amplitude
- 4.51%
- 52wk High
- 91.62
- Volume Ratio
- 0.40
- Turnover Ratio
- 2.06%
R&G Pharma Analyst Rating
View MoreForecast & Rating
Mar 29, 2026Price forecast
¥74.0056.78%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Wallstreetcn · Feb 2 at 09:45 AM
Novo Nordisk announced the main clinical trial results of Reimagine 2. Novo Cagrisema demonstrated a weight loss effect of up to 14.2%. Cagrisema shows better weight loss effects compared to Semaglutide
- Wallstreetcn · Jan 14 at 07:50 PM
AI healthcare and AI pharmaceutical concepts are experiencing volatile adjustments, with PR falling over 18%, R&G Pharma down nearly 15%, and IMIC, BOJI CRO, GOODWILL, and Berry Genomics all dropping more than 5%
- Zhitong · Oct 31, 2025 at 03:44 AM
R&G Pharma: Abnormal fluctuations in stock trading
- Zhitong · Oct 28, 2025 at 05:05 AM
R&G Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 95.5668 million yuan, an increase of 13.21%
- Zhitong · Sep 5, 2025 at 06:20 AM
R&G Pharma plans to launch an employee stock ownership plan in 2025 with a total funding not exceeding 15 million yuan
- Zhitong · Aug 27, 2025 at 06:13 AM
R&G Pharma: Net profit of 61.1161 million yuan in the first half of 2025, a year-on-year increase of 4.45%
